Clinical trial
Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer
NCT00387153 · Myriad Therapeutics, Inc., Industry · Terminated
Key facts
| NCT number | NCT00387153 |
|---|---|
| Title | Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer |
| Official title | Phase 1 OL, Dose Escalating, Multiple Dose Study To Determine The Safety, Tolerability, MTD, And Pharmacokinetics Of MPC-2130 Administered As Daily IV Infusions For 5 Days, Repeated Every 21 Days, In Patients With Refractory Cancer |
| Lead sponsor | Myriad Therapeutics, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | MPC-2130 |
| Enrollment | 8 |
| Start date | Aug 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Oct 12, 2006 |
| Last update posted | Nov 3, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: